ResearchDurability of Sotatercept Response in Pulmonary Hypertension: Insights From Extended Real-World Follow-Up
ResearchInvasive Versus Conservative Strategy in Older Adults ≥70 Years of Age With Non-ST-Segment-Elevation Myocardial Infarction: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis
ResearchEzetimibe vs Inclisiran in Coronary Artery Disease and Hyperlipidemia: A Propensity-Matched Analysis
ResearchAll-Cause and Cause-Specific Mortality Assessment in Patients Receiving Sodium Glucose Co-Transporter-2 Inhibitors
ResearchRacial and Sex Disparities in Patients With Takotsubo Cardiomyopathy With Inflammatory Bowel Disease
ResearchArtificial Intelligence in Breaking the Learning Curve for Echocardiography: A Secondary Analysis of a Multicentre Trial
ResearchTranscatheter Tricuspid Valve Intervention Versus Optimal Medical Therapy in Symptomatic Tricuspid Regurgitation: A Systematic Review and Meta-Analysis of Randomized and Observational Studies
ResearchGlucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy
ResearchCardiotoxicity and Peri-Operative Considerations in Immune Checkpoint Inhibitor and Chimeric Antigen Receptor T-Cell Therapy: A Narrative Review
ResearchIn-Hospital Outcomes of Percutaneous Left Ventricular Assist Device Recipients in Cardiogenic Shock Hospitalizations With Chronic Kidney Disease: A Nationwide Analysis
ResearchComparative Analysis of the DanGer Shock Trial to Randomized Cardiogenic Shock Trials and Real-World Registries
Jan 16, 2025LetterMedicare Coverage and Patient Out-of-Pocket Costs for Mavacamten.Written by 1 Roon author & 6 others Via The American Heart Association Journals